The Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia

Inclusion Criteria: * the patients aged 20 to 79 years with primary hypercholesterolemia that was not sufficiently responsive to therapeutic lifestyle changes and had LDL-C level over 100 mg/dL in high risk group. * Inclusion criteria was in accordance with drug treatment guidelines; coronary artery disease or equivalent group with LDL-C ≥100 mg/dl; patients with two or more risk factors and LDL-C≥130 mg/dl; patients with 0 or 1 risk factor and LDL-C \>160 mg/dl after therapeutic lifestyle changes Exclusion Criteria: * therapy with any other investigational drug within 30 days of randomization, * history of hypersensitivity to HMG-CoA reductase inhibitors, * uncontrolled hypertension, * poorly controlled diabetes (glycosylated hemoglobin \[HbA1c\] \>9%), * unstable angina or presented with new-onset myocardial infarction (within 6 months), * creatinine \>2.5 mg/dl, * alanine aminotransferase (ALT) \>2 x upper limit of normal (ULN), aspartate aminotransferase(AST) \>2 x ULN, or creatine kinase (CK) \>2 x ULN, * history of malignancy or psychosis; * chronic liver disease, * drug or alcohol abuse, pregnancy, breastfeeding, failure to practice adequate contraception, cyclical hormonal contraceptives or intermittent use of hormone replacement therapies.